The CDMO Lonza and Bristol Myers Squibb have announced an exclusive single-target licensing agreement.
Under the terms of this agreement, BMS will obtain exclusive access to Lonza's SYNtecan linker-payload platform to develop an antibody-drug conjugate (ADC) targeting an undisclosed antigen, as well as be gratned access to the GlycoConnect and HydraSpace technologies.
BMS will be responsible for the research, development, manufacturing and commercialisation of the ADC.
Lonza, through one of its affiliated companies, will be eligible to receive upfront payments, potential milestone payments and royalty payments based on the net sales of the resulting products.
Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis, Lonza, said: "BMS has long been at the forefront of innovation in our industry and this agreement marks a significant achievement in our collaboration with BMS.
Licensing SYNtecan linker-payloads, our TOPO1 inhibitor platform, to BMS provides another strong validation of its strength and its trustworthiness in delivering positive clinical outcomes.
"We are pleased to add BMS to our partnered pipeline, as we collaborate to advance therapies that provide meaningful treatments to individuals who are still facing a critical unmet medical need."
